Tofacitinib has been approved by the US FDA for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) in children aged 2 years and older, particularly for patients who have shown inadequate response or intolerance to one or more TNF inhibitors (14). The gene discussed is TNF; the disease is juvenile idiopathic arthritis.